Wisconsin Attorney General & University of Wisconsin System Partner with Adapt Pharma® to Increase Access to NARCAN® (naloxone HCl) Nasal Spray

November 14, 2017

Wisconsin Attorney General & University of Wisconsin System Partner with Adapt Pharma® to Increase Access to NARCAN® (naloxone HCl) Nasal Spray

More than 135,000 students across 10 campuses may benefit from this recent expansion of the free NARCAN® (naloxone HCI) Nasal Spray for Schools program  

Dublin – November 14, 2017 – Adapt Pharma, Inc. (www.adaptpharma.com), together with Attorney General Brad Schimel, today announced a partnership with the Wisconsin Department of Justice, Training and Standards Bureau and University of Wisconsin System to provide a limited number of free doses of NARCAN® (naloxone HCl) Nasal Spray 4mg across 10 campuses, reaching more than 135,000 students statewide.

The rate of opioid deaths in Wisconsin has nearly doubled in the last decade, and in 2015 the majority of opioid-related deaths (63%) involved the use of prescription drugs.[1] Naloxone helps reverse the effect of a potentially fatal opioid overdose and is increasingly being used by law enforcement, schools and communities.

“Earlier this year, we partnered with ADAPT Pharma to expand NARCAN access in Wisconsin and I’m pleased to once again be partnering with ADAPT Pharma to extend NARCAN’s reach throughout our state,” said Attorney General Schimel. “I appreciate University of Wisconsin System President Cross’ commitment to Wisconsin college students and look forward to beginning our new partnership that will allow the campus to have this potentially life-saving medication on hand.”

NARCAN® Nasal Spray 4mg is the only FDA-approved, needle-free formulation of naloxone for the emergency treatment of a known or suspected opioid overdose. NARCAN® Nasal Spray does not take the place of emergency medical care. It does not require assembly nor any specialized medical training in order to be administered. NARCAN® Nasal Spray delivers the highest concentrated dose of naloxone currently available. Additional doses of NARCAN® Nasal Spray may be required until emergency medical assistance arrives.

“The NARCAN® Nasal Spray for Schools program demonstrates the important role academic institutions have in educating students about opioid abuse and the risk of opioid pain medications,” said Mike Kelly, President of U.S. Operations at Adapt Pharma. “We applaud the University of Wisconsin System’s leadership in preparing its campuses for an opioid overdose emergency.”

Law enforcement and campus security across 10 campuses will be provided NARCAN® Nasal Spray 4mg, including: UW-Green Bay, UW-La Crosse, UW-Madison, UW-Milwaukee, UW-Oshkosh, UW-Platteville, UW-River Falls, UW-Stevens Point, UW-Stout, and UW-Superior.

“This will be a critical resource for our campus communities, and we are very appreciative of the partnership with the Department of Justice to receive NARCAN from Adapt Pharma. The UW System has been actively working with recovery stakeholders in Wisconsin to demonstrate our shared commitment in the fight against opioid use, and this is an important tool for our officers,” said University of Wisconsin System President Ray Cross.

Adapt Pharma encourages all Title IV-eligible, degree-granting colleges and universities in the United States to apply to receive up to four free boxes (with two 4 milligram doses each) of NARCAN® Nasal Spray at www.narcan.com/partnerships.

More than 216 colleges and universities in 35 states have participated in the program since launching this past April. This builds upon the free NARCAN® Nasal Spray for High Schools Program, which has distributed approximately 5,550 free doses to high schools in 41 states.

NARCAN® Nasal Spray is not a substitute for emergency medical care. Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance. Please see Indications and Important Safety Information below.

Indications

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

Important Safety Information

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

Adverse Reactions:  The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

To report SUSPECTED ADVERSE REACTIONS, contact ADAPT Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information at: https://www.narcan.com/pdf/NARCAN-Prescribing-Information.pdf.

For additional information on NARCAN® Nasal Spray, please visit www.NARCAN.com.

ABOUT ADAPT PHARMA®
Adapt Pharma® is a privately-held pharmaceutical company committed to positively impacting the lives of patients. Adapt Pharma’s strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development, and FDA approved, pharmaceutical products. Adapt Pharma’s company headquarters is in Dublin, Ireland and its U.S. headquarters is in Radnor, Pennsylvania. For more information, please visit www.adaptpharma.com.

ADAPT PHARMA® MEDIA CONTACT INFORMATION
Thom Duddy
Executive Director – Communications 
Adapt Pharma®
thomas.duddy@AdaptPharma.com 
484-431-8223

 

[1] Wisconsin Department of Health Services, Division of Public Health. Select Opioid-Related Morbidity and Mortality Data for Wisconsin. Nov. 2016.